Hepion's lead NASH drug gets USAN name 'rencofilstat'

Hepion Pharmaceuticals, Inc.

USAN Council adopted 'rencofilstat' as nonproprietary name for CRV431, Hepion's lead NASH/liver disease drug.
The name will be used in future publications, conferences, and clinical development steps.
Hepion is a clinical-stage biopharma focusing on AI-driven therapies for NASH and other liver diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.